Glutathione is a tripeptide made of glutamate, cysteine and glycine. It is present in all mammalian tissues at 1–10 mM as the most abundant non-protein thiol, and it is central to the cell's defence against oxidative damage and to the detoxification of foreign compounds[1]. Most mammalian cells make their own.
It is also sold as a supplement, taken as capsules for general health or skin lightening, and given by intravenous drip. The evidence for these uses is much thinner than for its role inside cells. How much swallowed glutathione reaches the blood intact is uncertain; two short trials found no rise in measured levels, and one six-month trial found higher levels[2][3][4], and in 2019 and again in 2026 the FDA warned about serious reactions to injected glutathione made from unsuitable raw material[5][6].
| Structure | γ-L-glutamyl-L-cysteinyl-glycine (γ-Glu-Cys-Gly) |
|---|---|
| Formula | C10H17N3O6S |
| Molecular weight | 307.3 Da (reduced, GSH); 612.6 Da (oxidised, GSSG); calculated |
| Broken down by | GGT on the outer surface of cells; ChaC1 in the cytosol |
| Concentration in tissues | 1–10 mM, highest in the liver |
| Made by | Two ATP-dependent enzymes in the cytosol |
| Uses as a product | Dietary supplement; intravenous use in compounding |
An unusual tripeptide
Two features make glutathione different from an ordinary tripeptide. The first is the bond between glutamate and cysteine. In a normal peptide, each amino acid is linked through its α-carboxyl group. In glutathione, glutamate is linked through the carboxyl group at the end of its side chain, the γ-carboxyl. Ordinary peptidases do not cut this bond. Outside cells it is cleaved by γ-glutamyltranspeptidase (GGT), an enzyme on the outer surface of certain cell types[1]. A 2012 study described a second route, inside the cell. The enzyme ChaC1, located in the cytosol of mammalian cells and switched on by stress in the endoplasmic reticulum, cuts the γ-bond of glutathione and releases 5-oxoproline and cysteinyl-glycine. It acts on glutathione but hardly on other γ-glutamyl compounds. The researchers showed the activity with purified mouse ChaC1 and studied its effects in yeast cells, where expressing the enzyme lowered glutathione by about half and increased cell death[7]. The γ-bond therefore protects glutathione from ordinary peptidases, not from breakdown as such.
The second is the thiol (–SH) group of cysteine, which makes glutathione a reducing agent. When the enzyme glutathione peroxidase reduces hydrogen peroxide or organic peroxides, two glutathione molecules are oxidised and joined through a disulfide bond, forming GSSG; glutathione reductase turns GSSG back into GSH using NADPH[1]. In cells the reduced form dominates and accounts for more than 98% of the total; most of it, 80–85%, is in the cytosol, with 10–15% in mitochondria[1]. The ratio of GSH to GSSG is used as a measure of the cell's oxidative state.
How cells make and recycle it
Glutathione is made in the cytosol in two ATP-consuming steps. Glutamate-cysteine ligase (GCL) first joins glutamate and cysteine into γ-glutamylcysteine; glutathione synthetase then adds glycine. The first step limits the rate. It is controlled by the supply of cysteine and by glutathione itself, which inhibits the enzyme when its own concentration is high[1].
Cells also export glutathione. Outside the cell, GGT cleaves the γ-bond and transfers the glutamyl group to another amino acid, cystine being the best acceptor; the pieces are taken back into cells and used to make new glutathione; this route is known as the γ-glutamyl cycle. Most of the glutathione in blood plasma comes from the liver[1]. Inside cells glutathione turns over quickly: in rat liver cytosol its half-life is 2–3 hours[1].
These roles are the basis of its reputation: removing peroxides, binding drugs and toxins so that they can be excreted, keeping protein thiols reduced, storing cysteine and taking part in cell signalling[1]. They describe glutathione made inside the cell, not glutathione taken as a product.
Glutathione taken by mouth
The γ-bond does not protect glutathione in the gut, where GGT in the intestine and liver can break it down[2]. Three trials in healthy adults measured whether swallowed glutathione raises glutathione levels in the body:
| Study | Dose and duration | Result |
|---|---|---|
| Witschi 1992, 7 people | One dose, about 3 g for a 70 kg adult | No rise in plasma glutathione over 4.5 hours |
| Allen 2011, 40 people | 1 g a day for 4 weeks | No change in red-cell glutathione or oxidative stress markers |
| Richie 2015, 54 people | 250 mg or 1 g a day for 6 months | Levels rose 30–35% in blood cells and plasma at the higher dose |
Witschi used 0.15 mmol per kg body weight[2]; Allen gave 500 mg twice daily[3]; Richie measured whole blood, red cells, plasma, lymphocytes and cheek cells[4]. All three were placebo-controlled except Witschi, which had no control group.
The two shorter studies found no effect on what they measured. A single dose did not raise glutathione, cysteine or glutamate in plasma, and the authors concluded that the systemic availability of oral glutathione in humans is negligible[2]. Four weeks of daily supplementation also changed neither glutathione in red blood cells nor markers of oxidative damage[3].
The six-month trial reported the opposite. Levels rose in all the compartments measured, by 30–35% in red cells, plasma and lymphocytes and by 260% in cheek cells at the higher dose, and returned to baseline one month after stopping[4]. The principal investigator received research support from the company that supplied the glutathione[4]. The trials differ in duration, dose and what they measured. None of them shows how much intact glutathione crosses the intestine: higher levels could also come from cells making more glutathione from the amino acids released in the gut. And none tested a health outcome; higher glutathione in a blood sample is a laboratory finding, not evidence that the person is healthier.
Skin lightening
Glutathione is widely promoted for lightening the skin. The best-known controlled trial, from Chulalongkorn University in Bangkok, gave 60 healthy medical students 500 mg of glutathione a day or placebo for four weeks. The melanin index fell at all six measured sites with glutathione, but the difference from placebo was statistically significant at only two: the right side of the face and the sun-exposed left forearm. Both groups tolerated the capsules well. The authors concluded that oral glutathione lightened the skin "in a small number of subjects" and that long-term safety had not been established[8].
The trial was small and short, and with six sites tested, two significant results could partly be due to chance. It does not show a reliable or lasting effect. The study was supported in part by the company that supplied the capsules[8].
Intravenous glutathione and FDA warnings
Intravenous glutathione is given in clinics, often as part of vitamin drips. In the United States, injectable glutathione is made by compounding pharmacies; there is no FDA-approved glutathione drug[9]. The recent FDA and CDC warnings concern contaminated and unsuitable raw material.
- 2019. The FDA told compounders not to use glutathione powder from one distributor for sterile injections after seven patients had reactions ranging from nausea and vomiting to difficulty breathing; one was hospitalised immediately after an intravenous dose[5]. FDA laboratory tests later found excessive endotoxin, a toxic component of bacterial cell walls, in all samples of the powder, some at up to five times the appropriate limit. The powder was labelled "Caution: Dietary Supplement"[10].
- 2026. The FDA reported at least 30 patients with fever, chills, pain, dizziness, and shock-like or sepsis-like symptoms after intravenous glutathione, some of whom were hospitalised. The glutathione came from a lot labelled "dietary supplement grade", which the agency stated is not an appropriate ingredient for injectable drugs. Two pharmacies in Texas recalled their glutathione injections for elevated endotoxin levels[6]. In September 2026 the CDC reported more than 25 ill people in four states, after intravenous, subcutaneous or intramuscular injection; at least three were hospitalised, one in intensive care with shock. A third pharmacy recalled its glutathione and glutathione-containing infusions[9].
Supplement-grade material is not made to the standards required for something injected into the body. The FDA describes the reactions as consistent with excessive endotoxin exposure[6]. This is a problem of product quality, and it is separate from the question of whether injected glutathione does anything useful.
In short
- Glutathione is γ-glutamyl-cysteinyl-glycine. The γ-bond between glutamate and cysteine resists ordinary peptidases; GGT cleaves it outside cells and ChaC1 inside them.
- Its cysteine thiol makes it a reducing agent: glutathione peroxidase uses it to destroy peroxides, forming GSSG, which glutathione reductase converts back.
- Cells make it in two ATP-dependent steps, limited by the supply of cysteine and by feedback from glutathione itself.
- Oral trials in healthy adults measured glutathione levels and laboratory markers, not health. A single dose and a 4-week trial found no change in the outcomes they measured; a 6-month industry-supported trial found higher levels. None shows how much glutathione is absorbed intact, or that supplements improve health.
- In one small 4-week skin trial, oral glutathione beat placebo at two of six sites; that is not evidence of a reliable lightening effect.
- The FDA and CDC have reported adverse events, including hospitalisations, associated with injected glutathione made from supplement-grade powder; FDA tests in 2019 found endotoxin up to five times the limit.
References
- Lu SC (2013). Glutathione synthesis. Biochimica et Biophysica Acta 1830(5):3143–3153. DOI: 10.1016/j.bbagen.2012.09.008
- Witschi A, Reddy S, Stofer B, Lauterburg BH (1992). The systemic availability of oral glutathione. European Journal of Clinical Pharmacology 43(6):667–669. DOI: 10.1007/BF02284971
- Allen J, Bradley RD (2011). Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. Journal of Alternative and Complementary Medicine 17(9):827–833. DOI: 10.1089/acm.2010.0716
- Richie JP Jr, Nichenametla S, Neidig W, Calcagnotto A, Haley JS, Schell TD, Muscat JE (2015). Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. European Journal of Nutrition 54(2):251–263. DOI: 10.1007/s00394-014-0706-z
- U.S. Food and Drug Administration (2019). FDA warns compounders not to use glutathione from Letco Medical to compound sterile drugs. 1 February 2019. fda.gov
- U.S. Food and Drug Administration (2026). FDA reminds compounders not to use dietary supplement grade glutathione in injectables. Content current as of 27 August 2026. fda.gov
- Kumar A, Tikoo S, Maity S, Sengupta S, Sengupta S, Kaur A, Bachhawat AK (2012). Mammalian proapoptotic factor ChaC1 and its homologues function as γ-glutamyl cyclotransferases acting specifically on glutathione. EMBO Reports 13(12):1095–1101. DOI: 10.1038/embor.2012.156
- Arjinpathana N, Asawanonda P (2012). Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study. Journal of Dermatological Treatment 23(2):97–102. DOI: 10.3109/09546631003801619
- Centers for Disease Control and Prevention (2026). Adverse events linked to injectable glutathione compounded with dietary supplement grade ingredient: current situation. Updated 11 September 2026. cdc.gov
- U.S. Food and Drug Administration (2019). FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables. Compounding alert, 7 June 2019. fda.gov